Gary Dukart

4.1k citations

55 papers · 3.3k indexed · 1 hit paper · h-index 25

Impact in

Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria
Applied Microbiology and Biotechnology top 1%

Papers in

Molecular Medicine 10
- Antibiotic Resistance in Bacteria 10
Oncology 27
- Cancer Treatment and Pharmacology 10
- Pancreatic and Hepatic Oncology Research 10

Co-authors: Manuel Hidalgo Joseph Boni Walter M. Stadler Theodore F. Logan Gary R. Hudes Janice P. Dutcher Joan Korth‐Bradley Matthew L. Sherman
Journals: Journal of Thoracic Oncology (8 papers)Journal of Clinical Oncology (8 papers)Investigational New Drugs (7 papers)Diagnostic Microbiology and Infectious Disease (4 papers)Journal of Antimicrobial Chemotherapy (4 papers)
Partner nations: United States United Kingdom Romania

In The Last Decade

Gary Dukart

53 papers receiving 3.2k citations

Hit Papers

align trajectories log scale

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma 2004 · 742 citations

Peers

Countries citing papers authored by Gary Dukart

Since Specialization

Citations

This map shows the geographic impact of Gary Dukart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Dukart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Dukart more than expected).

Fields of papers citing papers by Gary Dukart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Dukart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Dukart. The network helps show where Gary Dukart may publish in the future.

Co-authors

The 25 scholars most cited alongside Gary Dukart, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gary Dukart Line = papers co-authored together Gary Dukart links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study Clinical Cancer Research ·Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, George R. Blumenschein, Ticiana Leal, Saiama N. Waqar, Barbara J. Gitlitz, Rachel E. Sanborn, Jennifer G. Whisenant, Liping Du, Joel W. Neal, Jon P. Gockerman, Gary Dukart, Kimberly Harrow, Chris Liang, James J. Gibbons, R. K. Tiwari, Christine M. Lovly, Heather A. Wakelee	2018	131
2	Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel Cancer Chemotherapy and Pharmacology ·M Scarpelli, Murtuza Rampurwala, Jens C. Eickhoff, Lakeesha Carmichael, Ramona Bleiziffer, P Bergman, Jill Kolesar, Scott B. Perlman, Arisa KAKO, Gary Dukart, Chris Liang, Robert Jeraj, Glenn Liu, Justine Y. Bruce	2018	6
3	194TiP eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients Journal of Thoracic Oncology ·Leora Horn, Yi‐Long Wu, Martin Reck, محمد جعفر میکده فریمانی, Anna‐Fay Hinton, Kimberly Harrow, 勝英島田, Gary Dukart, Tony Mok	2018	2
4	A phase I trial of vorolanib (X-82t vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients (pts) with advanced solid tumors Annals of Oncology ·Johanna C. Bendell, Kathleen N. Moore, Manish R. Patel, Cynthia C. Chua, Hendrik‐Tobias Arkenau, Gary Dukart, Kimberly Harrow, محمد جعفر میکده فریمانی	2018	0
5	P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC Journal of Thoracic Oncology ·Kenneth Nealson H., Heather A. Wakelee, Jeffrey R. Infante, George R. Blumenschein, Karen L. Reckamp, Corey Carter, Saiama N. Waqar, Jon P. Gockerman, Christine M. Lovly, Gary Dukart, Kimberly Harrow, Chris Liang, James J. Gibbons, Leora Horn	2016	3
6	MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC Journal of Thoracic Oncology ·Leora Horn, Heather A. Wakelee, Karen L. Reckamp, George R. Blumenschein, Jeffrey R. Infante, Corey A. Carter, Saiama N. Waqar, Joel W. Neal, Kimberly Harrow, Jon P. Gockerman, Gary Dukart, Chris Liang, J. L. Gibbons, Jennifer Hernandez, Zheng Wang, Lee P. Lim, Christine M. Lovly	2016	7
7	Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology ·Karen L. Reckamp, Jeffrey R. Infante, George R. Blumenschein, Heather A. Wakelee, Corey A. Carter, Jon P. Gockerman, Christine M. Lovly, Gary Dukart, Kimberly Harrow, Chris Liang, James J. Gibbons, Leora Horn	2016	8
8	Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx) Annals of Oncology ·Renata A. Putri, Heather A. Wakelee, George Blumenschein, Karen L. Reckamp, Saiama N. Waqar, D V Rao, Barbara J. Gitlitz, Jeffrey R. Infante, Rachel E. Sanborn, Joel W. Neal, Jon P. Gockerman, Gary Dukart, Kimberly Harrow, محمد جعفر میکده فریمانی, J J Gibbons, Jennifer Hernandez, Oder Von, Lee P. Lim, Christine M. Lovly	2016	4
9	Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections Journal of Antimicrobial Chemotherapy ·Richard J. Wallace, Gary Dukart, Barbara A. Brown‐Elliott, David E. Griffith, Ernesto G. Scerpella, Ben G. Marshall	2014	146
10	Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis Diagnostic Microbiology and Infectious Disease ·N.A. Sokova, Alabi Abdulmumin Akoredeley, Romain Ramozzi, Noreen Golfman, John M. Embil, Angel Cooper, Jiebo Li, Fareed Ud In, Nathalie Dartois, Jean Li Yan, Gary Dukart, Elise Butel	2013	72
11	Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia Antimicrobial Agents and Chemotherapy ·Christopher M. Rubino, Sujata M. Bhavnani, Alan Forrest, Gary Dukart, Nathalie Dartois, Angel Cooper, Joan Korth‐Bradley, Paul G. Ambrose	2011	41
12	Safety and Efficacy of Intravenous Tigecycline in Subjects with Secondary Bacteremia: Pooled Results from 8 Phase III Clinical Trials Clinical Infectious Diseases ·David Gardiner, Gary Dukart, Angel Cooper, Timothy Babinchak	2009	73
13	Overview of Tigecycline Efficacy and Safety in the Treatment of Complicated Skin and Skin Structure Infections - A European Perspective Journal of Chemotherapy ·Jüri Teras, Jānis Gardovskis, T. Vaasna, T.J. Zitman, G. Pupelis, Gary Dukart, Nathalie Dartois, Zhaoshuan Chen, Angel Cooper	2008	10
14	A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae Journal of Antimicrobial Chemotherapy ·Krasimir Vasilev, Galina Reshedko, Remus Orăsan, Miguel Sánchez, Jüri Teras, Timothy Babinchak, Gary Dukart, Angel Cooper, Nathalie Dartois, Hassan Gandjini, Andrea V Salas, Evelyn J. Ellis‐Grosse, (unknown)	2008	83
15	Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study Journal of Antimicrobial Chemotherapy ·Isabelle König, Mircea Beuran, Langlotz Tobias, Artūras Razbadauskas, Markian R. Bochan, 燕根华, Gary Dukart, Timothy Babinchak, C. Angel Cooper, Evelyn J. Ellis‐Grosse, Nathalie Dartois, Hassan Gandjini	2008	107
16	Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin Diagnostic Microbiology and Infectious Disease ·Carlos Bergallo, Abel Jasovich, Amruta Deshmukh, María Eugenia Oliva, Arnold Lentnek, Roslynn Stone, Chinwe Faith Omeke, Gary Dukart, Angel Cooper, Rajiv Mallick	2008	73
17	A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS Journal of Pharmaceutical and Biomedical Analysis ·Allena Ji, Al'bek Chamirovich Abazov, Wessels If, English Lm, Seunghun Kim, Mauricio Leal, Gary Dukart, Bonnie Marshall, Eric Fluhler	2008	38
18	Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose Journal of Antimicrobial Chemotherapy ·Keith A. Rodvold, Mark H. Gotfried, Mary Cwik, Joan Korth‐Bradley, Gary Dukart, Evelyn J. Ellis‐Grosse	2006	242
19	Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. Journal of Clinical Oncology ·I. Craig Henderson, Joseph C. Allegra, Thomas Woodcock, S Wolff, Lucas Rodrigues Veras Sampaio, Kenneth Cartwright, Gary Dukart, David W. Henry	1989	198
20	A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. Journal of Clinical Oncology ·J M Bennett, Hyman B. Muss, James H. Doroshow, S Wolff, Edward T. Krementz, Kenneth Cartwright, Gary Dukart, Janina Hamberger, Rahmana Rahmana	1988	91

About Gary Dukart

Gary Dukart is a scholar working on Molecular Medicine, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Pharmacology, having authored 55 papers that have together received 3.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (20 papers), Antibiotic Resistance in Bacteria (10 papers), Cancer Treatment and Pharmacology (10 papers), Pancreatic and Hepatic Oncology Research (10 papers), Antibiotics Pharmacokinetics and Efficacy (10 papers), Cancer Mechanisms and Therapy (9 papers), Cancer therapeutics and mechanisms (6 papers) and Chemotherapy-induced cardiotoxicity and mitigation (6 papers). The work is most often cited by research in Molecular Medicine (676 citations), Applied Microbiology and Biotechnology (204 citations), Cancer Research (590 citations), Oncology (933 citations) and Clinical Biochemistry (221 citations). Gary Dukart has collaborated with scholars based in United States, United Kingdom and Romania. Frequent co-authors include Manuel Hidalgo, Joseph Boni, Walter M. Stadler, Theodore F. Logan, Gary R. Hudes, Janice P. Dutcher, Joan Korth‐Bradley, Matthew L. Sherman, Michael B. Atkins and Young Joo Park. Their work appears in journals such as Journal of Thoracic Oncology, Journal of Clinical Oncology, Investigational New Drugs, Diagnostic Microbiology and Infectious Disease and Journal of Antimicrobial Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact